103 related articles for article (PubMed ID: 2379151)
1. Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules.
Frödin JE; Lefvert AK; Mellstedt H
Cancer Res; 1990 Aug; 50(16):4866-71. PubMed ID: 2379151
[TBL] [Abstract][Full Text] [Related]
2. A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
Saleh MN; Khazaeli MB; Grizzle WE; Wheeler RH; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio AF
Cancer Res; 1993 Oct; 53(19):4555-62. PubMed ID: 8402627
[TBL] [Abstract][Full Text] [Related]
3. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with metastasizing colo-rectal carcinoma with mouse monoclonal antibodies (Moab 17-1A): a progress report.
Frödin JE; Biberfeld P; Christensson B; Philstedt P; Sundelius S; Sylvén M; Wahren B; Koprowski H; Mellstedt H
Hybridoma; 1986 Jul; 5 Suppl 1():S151-61. PubMed ID: 3744379
[TBL] [Abstract][Full Text] [Related]
5. Anti-idiotypic antibodies to monoclonal antibody CO17-1A.
Herlyn D; Sears H; Iliopoulos D; Lubeck M; Douillard JY; Sindelar W; Tempero M; Mellstedt H; Maher M; Koprowski H
Hybridoma; 1986 Jul; 5 Suppl 1():S51-8. PubMed ID: 3488951
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of CO17-1A monoclonal antibody.
Lobuglio AF; Saleh M; Peterson L; Wheeler R; Carrano R; Huster W; Khazaeli MB
Hybridoma; 1986 Jul; 5 Suppl 1():S117-23. PubMed ID: 3488950
[TBL] [Abstract][Full Text] [Related]
7. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
[TBL] [Abstract][Full Text] [Related]
8. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
[TBL] [Abstract][Full Text] [Related]
9. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model.
Velders MP; van Rhijn CM; Briaire IH; Fleuren GJ; Warnaar SO; Litvinov SV
Cancer Res; 1995 Oct; 55(19):4398-403. PubMed ID: 7671252
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
13. Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans.
Khazaeli MB; Wheeler R; Rogers K; Teng N; Ziegler E; Haynes A; Saleh MN; Hardin JM; Bolmer S; Cornett J
J Biol Response Mod; 1990 Apr; 9(2):178-84. PubMed ID: 2341860
[TBL] [Abstract][Full Text] [Related]
14. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
15. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
16. Clinical effects of monoclonal antibodies (MAb 17-1A) in patients with metastatic colorectal carcinomas.
Frödin JE; Harmenberg U; Biberfeld P; Christensson B; Lefvert AK; Rieger A; Shetye J; Wahren B; Mellstedt H
Hybridoma; 1988 Aug; 7(4):309-21. PubMed ID: 3262566
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of the chimeric monoclonal antibody (c30.6) in patients with metastatic colorectal cancer.
Ward RL; Packham D; Smythe AM; Murray J; Anderson-Stewart P; Kitchen N; Muirhead R; Phillips P; Gray P; Bigg-Wither G; Prabakaran K; Freund J; Fullham M; Rule M; Dalley D; Meagher A; Hawkins NJ; Smith GM
Clin Cancer Res; 2000 Dec; 6(12):4674-83. PubMed ID: 11156219
[TBL] [Abstract][Full Text] [Related]
18. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer.
Hofheinz RD; al-Batran SE; Hartmann F; Hartung G; Jäger D; Renner C; Tanswell P; Kunz U; Amelsberg A; Kuthan H; Stehle G
Onkologie; 2003 Feb; 26(1):44-8. PubMed ID: 12624517
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of colorectal cancer with monoclonal antibodies].
Nielsen SE
Ugeskr Laeger; 1997 May; 159(21):3134-9. PubMed ID: 9198999
[TBL] [Abstract][Full Text] [Related]
20. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
